Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Capecitabine (oral)
Treatment for Colon and rectum cancer
Typical Dosage: 1250 mg/m2 orally twice daily for 14 days, then 7 days rest, every 3 weeks
Effectiveness
70%
Safety Score
30%
Clinical Trials
45
Participants
30K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
30
DangerousModerateSafe
Treatment Details
Dosage Range
1250 mg/m2 orally twice daily for 14 days, then 7 days rest, every 3 weeks
Time to Effect
6-9 weeks
Treatment Duration
6 months (adjuvant) or until progression (metastatic)
Evidence Quality
HIGHNumber Needed to Treat (NNT)
9(Treat 9 patients to see 1 additional successful outcome)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$18,000
Monitoring:$10,000
Side Effect Mgmt:$5,000
Total Annual:$33,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$30,000/QALY
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$110,000
Cost per Remission
$1,100,000
Comparison vs Fluorouracil/Leucovorin (IV)
Cost Difference
$-5,000/year
Less expensive
QALY Difference
0.00 QALYs
Same outcomes
Dominance
No dominance
Capecitabine (oral) Outcomes
for Colon and rectum cancer
Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+30%
Remission Rate
+3%
Common Side Effects
Hand-foot syndrome
+55%
Diarrhea
+50%
Fatigue
+60%
Nausea/Vomiting
+40%
Stomatitis
+25%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
3 active trials recruiting for Capecitabine (oral) in Colon and rectum cancer
Effect of Synbiotic Supplementation on the Prevention of Mucositis in Cancer Patients Undergoing Chemotherapy
NCT06576986RECRUITINGNA
80 participants
INTERVENTIONAL
Belo Horizonte, Brazil
Started: Dec 12, 2023
Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.
NCT07407465RECRUITINGPHASE2
42 participants
INTERVENTIONAL
Lyon, France +27 more
Started: Oct 20, 2025
Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study
NCT06234007RECRUITINGPHASE2
45 participants
INTERVENTIONAL
Wuhan, China
Started: Dec 1, 2023
Completed Clinical Trials
10 completed trials for Capecitabine (oral) in Colon and rectum cancer
Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer
NCT00532909COMPLETEDPHASE1
13 participants
INTERVENTIONAL
Stanford, United States
Started: Jul 1, 2006
Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer
NCT04534218COMPLETEDPHASE2
49 participants
INTERVENTIONAL
Besançon, France +2 more
Started: Oct 16, 2020
CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
NCT02861300COMPLETEDPHASE1, PHASE2
50 participants
INTERVENTIONAL
Cleveland, United States +1 more
Started: Sep 12, 2016
Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver
NCT00026234COMPLETEDPHASE2
75 participants
INTERVENTIONAL
Rochester, United States
Started: Feb 1, 2002
Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer
NCT00177307COMPLETEDPHASE2
40 participants
INTERVENTIONAL
Pittsburgh, United States
Started: Jan 1, 2005
GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors
NCT00084643COMPLETEDPHASE1
20 participants
INTERVENTIONAL
Duarte, United States
Started: May 1, 2004
Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer
NCT00416494COMPLETEDPHASE2
50 participants
INTERVENTIONAL
Started: Sep 1, 2003
Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
NCT00022698COMPLETEDPHASE2
67 participants
INTERVENTIONAL
Birmingham, United States +16 more
Started: May 1, 2001
Capecitabine and Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer
NCT00104689COMPLETEDPHASE2
60 participants
INTERVENTIONAL
Caen, France +8 more
Started: Jun 30, 2003
Oxaliplatin, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Rectum
NCT00086931COMPLETEDPHASE1, PHASE2
37 participants
INTERVENTIONAL
Buffalo, United States
Started: Sep 1, 2003
Showing 20 of 48 total trials